Public Citizen asks FDA to hold off on Pargluva approval

Share this article:
Consumer group Public Citizen has urged the FDA to hold off on approving Bristol-Myers Squibb and Merck's diabetes drug Pargluva (muraglitazar) because its use may increase the risk of heart failure and death in some patients.
"We question why a drug that an FDA medical officer has concluded causes dose-related edema, weight gain and congestive heart failure needs to be approved for diabetic patients who are already at increased risk for cardiovascular adverse effects and who already have multiple drugs available to treat their conditions," the consumer group wrote in a letter sent to the FDA last week.
The fate of the drug remains unclear.
In October, the FDA issued Bristol-Myers Squibb and Merck an approvable letter asking for more heart safety information before the FDA made a final decision. Company officials said it might take up to five years to compile the data.
Yesterday a Wall Street Journal report said that Bristol-Myers Squibb won't launch Pargluva until after 2007.
The newspaper report also said the company still has not decided whether it will pursue marketing approval for Pargluva and likely won't make a decision before next year.
Pargluva is the first drug in what had been considered a promising new class of drugs for millions of diabetics with some analysts predicting sales of more than $1 billion annually.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.